232 related articles for article (PubMed ID: 12824237)
1. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization.
Holzer MP; Solomon KD; Vroman DT; Sandoval HP; Margaron P; Kasper TJ; Crosson CE
Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2954-8. PubMed ID: 12824237
[TBL] [Abstract][Full Text] [Related]
2. Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models.
Framme C; Flucke B; Birngruber R
Graefes Arch Clin Exp Ophthalmol; 2006 Jul; 244(7):773-81. PubMed ID: 16440207
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic Therapy Leads to Time-Dependent Regression of Pathologic Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Allograft Survival.
Hou Y; Le VNH; Clahsen T; Schneider AC; Bock F; Cursiefen C
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5862-5869. PubMed ID: 29145577
[TBL] [Abstract][Full Text] [Related]
4. Regression of mature lymphatic vessels in the cornea by photodynamic therapy.
Bucher F; Bi Y; Gehlsen U; Hos D; Cursiefen C; Bock F
Br J Ophthalmol; 2014 Mar; 98(3):391-5. PubMed ID: 24414403
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy of corneal neovascularization with verteporfin.
Fossarello M; Peiretti E; Zucca I; Serra A
Cornea; 2003 Jul; 22(5):485-8. PubMed ID: 12827058
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes.
Berdugo M; Bejjani RA; Valamanesh F; Savoldelli M; Jeanny JC; Blanc D; Ficheux H; Scherz A; Salomon Y; BenEzra D; Behar-Cohen F
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1633-44. PubMed ID: 18385085
[TBL] [Abstract][Full Text] [Related]
7. Experimental inhibition of corneal neovascularization by photodynamic therapy with verteporfin.
Yoon KC; Ahn KY; Lee SE; Kim KK; Im SK; Oh HJ; Jeong IY; Park SW; Park YG; Nah HJ; Im WB
Curr Eye Res; 2006 Mar; 31(3):215-24. PubMed ID: 16531278
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
Ju M; Mailhos C; Bradley J; Dowie T; Ganley M; Cook G; Calias P; Lange N; Adamis AP; Shima DT; Robinson GS
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):662-70. PubMed ID: 18235012
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
Husain D; Kim I; Gauthier D; Lane AM; Tsilimbaris MK; Ezra E; Connolly EJ; Michaud N; Gragoudas ES; O'Neill CA; Beyer JC; Miller JW
Arch Ophthalmol; 2005 Apr; 123(4):509-16. PubMed ID: 15824225
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization.
Abdelkawi SA; Hassan AA
Gen Physiol Biophys; 2012 Dec; 31(4):449-55. PubMed ID: 23255672
[TBL] [Abstract][Full Text] [Related]
11. Comparison of photodynamic therapy with two different parameters combined with subconjunctival injection of bevacizumab for corneal neovascularization.
Yin XF; Wu MH; Jin CJ; Zhou SY
Photodiagnosis Photodyn Ther; 2024 Apr; 46():104067. PubMed ID: 38548042
[TBL] [Abstract][Full Text] [Related]
12. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization.
Zacks DN; Ezra E; Terada Y; Michaud N; Connolly E; Gragoudas ES; Miller JW
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2384-91. PubMed ID: 12091441
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of photosensitizer ATX-S10 (Na) in experimental corneal neovascularization.
Gohto Y; Obana A; Kaneda K; Nakajima S; Takemura T; Miki T
Jpn J Ophthalmol; 2000; 44(4):348-53. PubMed ID: 10974289
[TBL] [Abstract][Full Text] [Related]
14. [Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy].
Hamdan J; Boulze M; Aziz A; Alessi G; Hoffart L
J Fr Ophtalmol; 2015 Dec; 38(10):924-33. PubMed ID: 26522892
[TBL] [Abstract][Full Text] [Related]
15. [Neovascularization corneal regression in patients treated with photodynamic therapy with verteporfin].
Díaz-Dávalos CD; Carrasco-Quiroz A; Rivera-Díez D
Rev Med Inst Mex Seguro Soc; 2016; 54(2):164-9. PubMed ID: 26960043
[TBL] [Abstract][Full Text] [Related]
16. [Accumulation of a photosensitizer ATX-S 10 Na (II) to experimental corneal neovascularization].
Gohto Y; Obana A; Kaneda K; Nakajima S; Takemura T; Miki T
Nippon Ganka Gakkai Zasshi; 1998 Nov; 102(11):724-30. PubMed ID: 9852716
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy with verteporfin for corneal neovascularization.
Al-Torbak AA
Middle East Afr J Ophthalmol; 2012; 19(2):185-9. PubMed ID: 22623856
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma.
Parodi MB; Iacono P
Am J Ophthalmol; 2004 Jul; 138(1):157-8. PubMed ID: 15234305
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.
You IC; Im SK; Lee SH; Yoon KC
Cornea; 2011 Jan; 30(1):30-3. PubMed ID: 20861729
[TBL] [Abstract][Full Text] [Related]
20. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.
Chen B; Pogue BW; Zhou X; O'Hara JA; Solban N; Demidenko E; Hoopes PJ; Hasan T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):720-7. PubMed ID: 15701861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
